title: [Expression of B7-H1 protein in human pancreatic carcinoma tissues and its clinical significance].
abstract: OBJECTIVE
  B7-H1, a member of B7 family, is expressed in tumor cells and has emerged as an important immune modulator capable of suppressing host immunity by inhibiting T cells function. This study was to probe into the correlation between the expression level of B7-H1 protein in pancreatic carcinoma tissues and clinicopathological characteristics and prognosis.
  
  
  METHODS
  The expression of B7-H1 was measured in 40 cases of pancreatic carcinoma tissues and 10 cases of normal corresponding paracarcinoma tissues by immunohistochemistry. The relationship between the expression level of B7-H1 and clinicopathological characteristics and survival was analyzed.
  
  
  RESULTS
  The positive rate of B7-H1 was significantly higher in the tumor tissues [45.00% (18/40)] than in the normal corresponding paracarcinoma tissues [0(0/10)] (P<0.05); moreover, B7-H1 expression was significantly associated with the staging of tumor and preoperative serum CA19-9 level (P<0.05). The multivariate cox proportional hazards regression analysis of prognostic factors for overall survival and relapse-free survival showed that the expression of B7-H1 was an independent factor for poor prognosis.
  
  
  CONCLUSIONS
  B7-H1 protein was expressed in human pancreatic carcinoma tissues, and was associated with the prognosis.
authors: Department of Oncology, The First Affiliated Hospital, Soochow University, Suzhou, Jiangsu, 215006, P. R. China.
authors: Xiao-Ling
authors: XL
authors: Chen
authors: Su-Xu
authors: SX
authors: Yuan
authors: Chen
authors: C
authors: Chen
authors: Yi-Xiang
authors: YX
authors: Mao
authors: Gang
authors: G
authors: Xu
authors: Xian-Yuan
authors: XY
authors: Wang
mesh_terms: D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000378:metabolism*; D060890:B7-H1 Antigen; D018395:CA-19-9 Antigen / Q000097:blood; D044584:Carcinoma, Ductal / Q000097:blood / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D018282:Cystadenocarcinoma, Mucinous / Q000097:blood / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010180:Pancreatectomy / Q000379:methods; D010190:Pancreatic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D016016:Proportional Hazards Models
chemical_list: D015703:Antigens, CD; D060890:B7-H1 Antigen; D018395:CA-19-9 Antigen; C423236:CD274 protein, human